Colorectal Cancer Screening and Race in an Equal Access Medical System.

National colorectal cancer (CRC) screening rates have improved, but significant racial disparities have been identified. Improved access to care has been proposed as a solution to eliminate such disparities. To determine if racial disparities in CRC screening rates persist in a medical system without barriers to access or cost. A retrospective review study was performed, examining the healthcare effectiveness data and information set data from patients between the ages of 50 and 65 years who were eligible for CRC screening. Data on the type of CRC screening and rates of up-to-date screening were also examined. Data were available for 14,196 patients of whom 8809 (62%) reported race. Subjects included were 53% male and 47% female, with breakdown by race as follows: 53% White, 34% Asian/Pacific Islander, 11% Black, 1% Hispanic, and <1% Native-American. Overall, CRC screening and up-to-date rates were higher than the national average (81 and 72%, respectively). Blacks were less likely than non-Blacks to have undergone CRC screening (75 vs. 82%, p < 0.001), and were also less likely to be up-to-date with CRC screening (66 vs. 72%, p < 0.001). Despite elimination of access and cost barriers, racial disparities in CRC screening persist. Equal access to CRC screening tools will be necessary, but not sufficient, to eliminate the currently observed national trends. Further study should focus on elucidating patient-specific barriers to successful completion and maintenance of CRC screening.

Cytomegalovirus infection and the gastrointestinal tract.

Cytomegalovirus (CMV) infection is common worldwide, but the majority are asymptomatic. However, during initial infection or reactivation, CMV can cause tissue-invasive end-organ damage including in the gastrointestinal tract, especially in immunocompromised individuals. Gastrointestinal CMV disease can present with myriad of symptoms and be highly variable endoscopically. In this article we review the manifestations of CMV infection within the luminal gastrointestinal tract and discuss the options for diagnosis and management.

Diversity and clinical impact of Acinetobacter baumannii colonization and infection at a military medical center.

The epidemiology of Acinetobacter baumannii emerging in combat casualties is poorly understood. We analyzed 65 (54 nonreplicate) Acinetobacter isolates from 48 patients (46 hospitalized and 2 outpatient trainees entering the military) from October 2004 to October 2005 for genotypic similarities, time-space relatedness, and antibiotic susceptibility. Clinical and surveillance cultures were compared by amplified fragment length polymorphism (AFLP) genomic fingerprinting to each other and to strains of a reference database. Antibiotic susceptibility was determined, and multiplex PCR was performed for OXA-23-like, -24-like, -51-like, and -58-like carbapenemases. Records were reviewed for overlapping hospital stays of the most frequent genotypes, and risk ratios were calculated for any association of genotype with severity of Acute Physiology and Chronic Health Evaluation II (APACHE II) score or injury severity score (ISS) and previous antibiotic use. Nineteen genotypes were identified; two predominated, one consistent with an emerging novel international clone and the other unique to our database. Both predominant genotypes were carbapenem resistant, were present at another hospital before patients' admission to our facility, and were associated with higher APACHE II scores, higher ISSs, and previous carbapenem antibiotics in comparison with other genotypes. One predominated in wound and respiratory isolates, and the other predominated in wound and skin surveillance samples. Several other genotypes were identified as European clones I to III. Acinetobacter genotypes from recruits upon entry to the military, unlike those in hospitalized patients, did not include carbapenem-resistant genotypes. Acinetobacter species isolated from battlefield casualties are diverse, including genotypes belonging to European clones I to III. Two carbapenem-resistant genotypes were epidemic, one of which appeared to belong to a novel international clone.

Simeprevir for the treatment of chronic hepatitis C.

INTRODUCTION: The addition of protease inhibitors such as telaprevir and boceprevir with PEGylated interferon and ribavirin has significantly improved cure rates for genotype 1 hepatitis C virus (HCV) infection. Simeprevir (TMC435) is a second-generation protease inhibitor that is in development for the treatment of genotype 1 HCV infection. AREAS COVERED: The authors present: i) an overview of Phases I - III clinical trials of simeprevir for HCV infection based on peer-reviewed literature and congress presentations and ii) an evaluation of the efficacy and safety of simeprevir in the treatment of HCV infection. EXPERT OPINION: Simeprevir is a once-daily oral medication that combined with PEGylated interferon and ribavirin appears to be a potent and safe agent to treat genotype 1 HCV infection for patients who are treatment-naïve and prior treatment-failures. Compared to telaprevir and boceprevir, simeprevir will likely be the protease inhibitor of choice for genotype 1 HCV infection based on ease of use, lower rates of adverse events, including rash and anemia, and no significant reported drug-drug interactions. Associated side effects inherent with interferon-based regimens may be problematic for patients. As HCV therapies evolve into interferon-free regimens, simeprevir may potentially be combined with other oral direct-acting agents without interferon to treat HCV infection.